Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAHANCA 30
2024-516178-31-00Phase 3Authorised
- Sponsor
- Central Denmark Region
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised trial of nimorazole in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Central Denmark Region. Primary endpoint: Locoregional control after radiotherapy (not including possible salvage treatment). Planned start Nov 2024; status: authorised.
02
Drugs
nimorazole
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2024-516178-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516178-31-00.